CELLINK : establishes R&D lab in AstraZeneca’s BioVentureHub

PRESS RELEASE

Gothenburg 17thof January 2018, 16:15

CELLINK establishes R&D lab in AstraZeneca's BioVentureHub

New lab to specialize in oncology research, as well as bioprinted lung and heart tissue models

CELLINK, the Gothenburg-based creator of one of the world's first universal bioinks and a leading bioprinter developer and provider, is setting up a new lab that will enable thecompany to develop better kidney, heart, liver and lung tissue models for use in pharmaceutical development.

Located in the BioVentureHub, at the heart of AstraZeneca's R&D Gothenburg site, the newlab will be staffed by a team of four scientists and researchers. They will focus on developing opportunities for customers and partners to bioprint using any type of cells relevant to thetargeted applications.

The BioVentureHub continues to grow. With CELLINK onboard, and after 8 new companiesjoined in 2017, there are currently 25 companies and 1 academic group in the BioVentureHub.

Erik Gatenholm, (co-founder and CEO, CELLINK) "We are very happy to establish an R&D lab inAstraZeneca's BioVentureHub. It gives us a unique opportunity to collocate with, and tap into, the power of AstraZeneca's world-class scientists and facilities, as well as with the other exciting life science companies in the hub. Surrounded by experts in cardiovascular,metabolic, respiratory and oncology diseases, it's a truly inspiring environment in which todevelop our future offering of bioprinting technologies."

Magnus Björsne, (CEO, AstraZeneca BioVentureHub) "CELLINK is developing exciting 3D bioprinting technologies that are enabling new ways to study biological systems and develop better treatments. Delivering on our ambition to facilitate interactions between drug, device, diagnostic and digital health companies, Erik and the CELLINK team will undoubtedly addsignificant value to the innovation experiment we are building here at the BioVentureHub."

For further information, please contact:

Erik Gatenholm, CEO	Gusten Danielsson, CFO
Phone: [phone]	Phone: [phone]
E-mail:[e-mail]	E-mail:[e-mail]
About CELLINK

CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Mangold Fondkommission AB, tel: [phone], is the Company's Certified Adviser.